APO Research
Talk to an analyst

APO RESEARCH · REPORT

Meningococcal Disease Treatment

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Meningococcal Disease Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025198 pages

Choose your research edition.

Industry ResearchMeningococcal Disease Treatment Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Meningococcal Disease Treatment Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Meningococcal Disease Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Meningococcal Disease Treatment Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Meningococcal Disease Treatment Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Meningococcal Disease Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Meningococcal Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Meningococcal Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Meningococcal Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Meningococcal Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Meningococcal Disease Treatment include Walvax Biotechnology Co.,Ltd., Apeloa Pharmaceutical Co.,Ltd., Novartis, Merck Sharp & Dohme, Beijing Minhai Biological Technology Co.,Ltd., CanSino Biologics Inc., Shandong Jincheng Pharmaceutical Group Co.,ltd., Pfizer and Hebei Hejia Pharmaceutical Technology Group Co., Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Meningococcal Disease Treatment market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Meningococcal Disease Treatment and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Meningococcal Disease Treatment revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Meningococcal Disease Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Meningococcal Disease Treatment Segment by Company

Walvax Biotechnology Co.,Ltd.

Apeloa Pharmaceutical Co.,Ltd.

Novartis

Merck Sharp & Dohme

Beijing Minhai Biological Technology Co.,Ltd.

CanSino Biologics Inc.

Shandong Jincheng Pharmaceutical Group Co.,ltd.

Pfizer

Hebei Hejia Pharmaceutical Technology Group Co., Ltd

GlaxoSmithKline

Chengdu Institute of Biology

Sanofi Pasteur

Meningococcal Disease Treatment Segment by Type

Antibiotics

Vaccines

Meningococcal Disease Treatment Segment by Application

Hospitals

Drugstores

Others

Meningococcal Disease Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Disease Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Meningococcal Disease Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Meningococcal Disease Treatment industry.

Chapter 3: Detailed analysis of Meningococcal Disease Treatment companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Meningococcal Disease Treatmentrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Meningococcal Disease Treatment Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Antibiotics Table 3. Key Players of Vaccines Table 4. Global Meningococcal Disease Treatment Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Hospitals Table 6. Key Players of Drugstores Table 7. Key Players of Others Table 8. Global Meningococcal Disease Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Meningococcal Disease Treatment Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Meningococcal Disease Treatment Market Share by Region (2021-2026) Table 11. Global Meningococcal Disease Treatment Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Meningococcal Disease Treatment Market Share by Region (2027-2032) Table 13. Meningococcal Disease Treatment Industry Trends Table 14. Meningococcal Disease Treatment Industry Drivers Table 15. Meningococcal Disease Treatment Industry Opportunities and Challenges Table 16. Meningococcal Disease Treatment Industry Restraints Table 17. Global Meningococcal Disease Treatment Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Meningococcal Disease Treatment Revenue Market Share by Company (2021-2026) Table 19. Global Meningococcal Disease Treatment Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Meningococcal Disease Treatment Key Company Head Office and Area Served Table 21. Global Meningococcal Disease Treatment Company, Product Type & Application Table 22. Global Meningococcal Disease Treatment Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Meningococcal Disease Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Meningococcal Disease Treatment Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Meningococcal Disease Treatment Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Meningococcal Disease Treatment Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Meningococcal Disease Treatment Revenue Market Share by Type (2021-2026) Table 29. Global Meningococcal Disease Treatment Revenue Market Share by Type (2027-2032) Table 30. Global Meningococcal Disease Treatment Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Meningococcal Disease Treatment Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Meningococcal Disease Treatment Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Meningococcal Disease Treatment Revenue Market Share by Application (2021-2026) Table 34. Global Meningococcal Disease Treatment Revenue Market Share by Application (2027-2032) Table 35. Walvax Biotechnology Co.,Ltd. Company Information Table 36. Walvax Biotechnology Co.,Ltd. Business Overview Table 37. Walvax Biotechnology Co.,Ltd. Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Walvax Biotechnology Co.,Ltd. Meningococcal Disease Treatment Product Portfolio Table 39. Walvax Biotechnology Co.,Ltd. Recent Development Table 40. Apeloa Pharmaceutical Co.,Ltd. Company Information Table 41. Apeloa Pharmaceutical Co.,Ltd. Business Overview Table 42. Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Treatment Product Portfolio Table 44. Apeloa Pharmaceutical Co.,Ltd. Recent Development Table 45. Novartis Company Information Table 46. Novartis Business Overview Table 47. Novartis Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Novartis Meningococcal Disease Treatment Product Portfolio Table 49. Novartis Recent Development Table 50. Merck Sharp & Dohme Company Information Table 51. Merck Sharp & Dohme Business Overview Table 52. Merck Sharp & Dohme Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Merck Sharp & Dohme Meningococcal Disease Treatment Product Portfolio Table 54. Merck Sharp & Dohme Recent Development Table 55. Beijing Minhai Biological Technology Co.,Ltd. Company Information Table 56. Beijing Minhai Biological Technology Co.,Ltd. Business Overview Table 57. Beijing Minhai Biological Technology Co.,Ltd. Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Beijing Minhai Biological Technology Co.,Ltd. Meningococcal Disease Treatment Product Portfolio Table 59. Beijing Minhai Biological Technology Co.,Ltd. Recent Development Table 60. CanSino Biologics Inc. Company Information Table 61. CanSino Biologics Inc. Business Overview Table 62. CanSino Biologics Inc. Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. CanSino Biologics Inc. Meningococcal Disease Treatment Product Portfolio Table 64. CanSino Biologics Inc. Recent Development Table 65. Shandong Jincheng Pharmaceutical Group Co.,ltd. Company Information Table 66. Shandong Jincheng Pharmaceutical Group Co.,ltd. Business Overview Table 67. Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Treatment Product Portfolio Table 69. Shandong Jincheng Pharmaceutical Group Co.,ltd. Recent Development Table 70. Pfizer Company Information Table 71. Pfizer Business Overview Table 72. Pfizer Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Pfizer Meningococcal Disease Treatment Product Portfolio Table 74. Pfizer Recent Development Table 75. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Company Information Table 76. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Business Overview Table 77. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Treatment Product Portfolio Table 79. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Recent Development Table 80. GlaxoSmithKline Company Information Table 81. GlaxoSmithKline Business Overview Table 82. GlaxoSmithKline Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. GlaxoSmithKline Meningococcal Disease Treatment Product Portfolio Table 84. GlaxoSmithKline Recent Development Table 85. Chengdu Institute of Biology Company Information Table 86. Chengdu Institute of Biology Business Overview Table 87. Chengdu Institute of Biology Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 88. Chengdu Institute of Biology Meningococcal Disease Treatment Product Portfolio Table 89. Chengdu Institute of Biology Recent Development Table 90. Sanofi Pasteur Company Information Table 91. Sanofi Pasteur Business Overview Table 92. Sanofi Pasteur Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 93. Sanofi Pasteur Meningococcal Disease Treatment Product Portfolio Table 94. Sanofi Pasteur Recent Development Table 95. North America Meningococcal Disease Treatment Market Size by Type (2021-2026) & (US$ Million) Table 96. North America Meningococcal Disease Treatment Market Size by Type (2027-2032) & (US$ Million) Table 97. North America Meningococcal Disease Treatment Market Size by Application (2021-2026) & (US$ Million) Table 98. North America Meningococcal Disease Treatment Market Size by Application (2027-2032) & (US$ Million) Table 99. North America Meningococcal Disease Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. North America Meningococcal Disease Treatment Market Size by Country (2021-2026) Table 101. North America Meningococcal Disease Treatment Market Size by Country (2027-2032) Table 102. Europe Meningococcal Disease Treatment Market Size by Type (2021-2026) & (US$ Million) Table 103. Europe Meningococcal Disease Treatment Market Size by Type (2027-2032) & (US$ Million) Table 104. Europe Meningococcal Disease Treatment Market Size by Application (2021-2026) & (US$ Million) Table 105. Europe Meningococcal Disease Treatment Market Size by Application (2027-2032) & (US$ Million) Table 106. Europe Meningococcal Disease Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. Europe Meningococcal Disease Treatment Market Size by Country (2021-2026) Table 108. Europe Meningococcal Disease Treatment Market Size by Country (2027-2032) Table 109. China Meningococcal Disease Treatment Market Size by Type (2021-2026) & (US$ Million) Table 110. China Meningococcal Disease Treatment Market Size by Type (2027-2032) & (US$ Million) Table 111. China Meningococcal Disease Treatment Market Size by Application (2021-2026) & (US$ Million) Table 112. China Meningococcal Disease Treatment Market Size by Application (2027-2032) & (US$ Million) Table 113. Asia Meningococcal Disease Treatment Market Size by Type (2021-2026) & (US$ Million) Table 114. Asia Meningococcal Disease Treatment Market Size by Type (2027-2032) & (US$ Million) Table 115. Asia Meningococcal Disease Treatment Market Size by Application (2021-2026) & (US$ Million) Table 116. Asia Meningococcal Disease Treatment Market Size by Application (2027-2032) & (US$ Million) Table 117. Asia Meningococcal Disease Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. Asia Meningococcal Disease Treatment Market Size by Country (2021-2026) Table 119. Asia Meningococcal Disease Treatment Market Size by Country (2027-2032) Table 120. South America, Middle East & Africa Meningococcal Disease Treatment Market Size by Type (2021-2026) & (US$ Million) Table 121. South America, Middle East & Africa Meningococcal Disease Treatment Market Size by Type (2027-2032) & (US$ Million) Table 122. South America, Middle East & Africa Meningococcal Disease Treatment Market Size by Application (2021-2026) & (US$ Million) Table 123. South America, Middle East & Africa Meningococcal Disease Treatment Market Size by Application (2027-2032) & (US$ Million) Table 124. South America, Middle East & Africa Meningococcal Disease Treatment Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 125. South America, Middle East & Africa Meningococcal Disease Treatment Market Size by Country (2021-2026) Table 126. South America, Middle East & Africa Meningococcal Disease Treatment Market Size by Country (2027-2032) Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Meningococcal Disease Treatment Product Image Figure 2. Global Meningococcal Disease Treatment Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Meningococcal Disease Treatment Market Share by Type: 2025 VS 2032 Figure 4. Antibiotics Image Figure 5. Vaccines Image Figure 6. Global Meningococcal Disease Treatment Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 7. Global Meningococcal Disease Treatment Market Share by Application: 2025 VS 2032 Figure 8. Hospitals Image Figure 9. Drugstores Image Figure 10. Others Image Figure 11. Global Meningococcal Disease Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 13. Global Meningococcal Disease Treatment Market Share by Region: 2025 VS 2032 Figure 14. Years Considered Figure 15. Global Meningococcal Disease Treatment Market Share by Players in 2025 Figure 16. Global Top 5 and 10 Meningococcal Disease Treatment Players Market Share by Revenue in 2025 Figure 17. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Meningococcal Disease Treatment Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Meningococcal Disease Treatment Revenue Market Share by Type (2021-2032) Figure 20. Global Meningococcal Disease Treatment Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Meningococcal Disease Treatment Revenue Market Share by Application (2021-2032) Figure 22. North America Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 23. North America Meningococcal Disease Treatment Market Share by Type (2021-2032) Figure 24. North America Meningococcal Disease Treatment Market Share by Application (2021-2032) Figure 25. North America Meningococcal Disease Treatment Market Share by Country (2021-2032) Figure 26. United States Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 27. Canada Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 28. Mexico Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 29. Europe Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 30. Europe Meningococcal Disease Treatment Market Share by Type (2021-2032) Figure 31. Europe Meningococcal Disease Treatment Market Share by Application (2021-2032) Figure 32. Europe Meningococcal Disease Treatment Market Share by Country (2021-2032) Figure 33. Germany Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 34. France Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 35. U.K. Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 36. Italy Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 37. Russia Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 38. Nordic Countries Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 39. China Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 40. China Meningococcal Disease Treatment Market Share by Type (2021-2032) Figure 41. China Meningococcal Disease Treatment Market Share by Application (2021-2032) Figure 42. Asia Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 43. Asia Meningococcal Disease Treatment Market Share by Type (2021-2032) Figure 44. Asia Meningococcal Disease Treatment Market Share by Application (2021-2032) Figure 45. Asia Meningococcal Disease Treatment Market Share by Country (2021-2032) Figure 46. Japan Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 47. South Korea Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 48. Taiwan Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 49. Southeast Asia Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 50. India Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 51. Australia Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 52. South America, Middle East & Africa Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Meningococcal Disease Treatment Market Share by Type (2021-2032) Figure 54. South America, Middle East & Africa Meningococcal Disease Treatment Market Share by Application (2021-2032) Figure 55. South America, Middle East & Africa Meningococcal Disease Treatment Market Share by Country (2021-2032) Figure 56. Brazil Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 57. South Africa Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 58. Saudi Arabia Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 59. Turkey Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 60. Argentina Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 61. UAE Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 62. Egypt Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 63. Chile Meningococcal Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 64. Research Process Figure 65. Key Executives Interviewed

Scope & coverage.

Types
  • Antibiotics
  • Vaccines
Applications
  • Hospitals
  • Drugstores
  • Others
Companies covered
  • Walvax Biotechnology Co.,Ltd.
  • Apeloa Pharmaceutical Co.,Ltd.
  • Novartis
  • Merck Sharp & Dohme
  • Beijing Minhai Biological Technology Co.,Ltd.
  • CanSino Biologics Inc.
  • Shandong Jincheng Pharmaceutical Group Co.,ltd.
  • Pfizer
  • Hebei Hejia Pharmaceutical Technology Group Co., Ltd
  • GlaxoSmithKline
  • Chengdu Institute of Biology
  • Sanofi Pasteur

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Meningococcal Disease Treatment Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Antibiotics
  5. 1.2.3 Vaccines
  6. 1.3 Market Analysis by Application
  7. 1.3.1 Global Meningococcal Disease Treatment Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  8. 1.3.2 Hospitals
  9. 1.3.3 Drugstores
  10. 1.3.4 Others
  11. 1.4 Global Market Growth Prospects
  12. 1.5 Global Meningococcal Disease Treatment Growth Trends by Region
  13. 1.5.1 Global Meningococcal Disease Treatment Market Size by Region: 2021 VS 2025 VS 2032
  14. 1.5.2 Meningococcal Disease Treatment Market Size by Region (2021-2026)
  15. 1.5.3 Meningococcal Disease Treatment Market Size by Region (2027-2032)
  16. 1.6 Assumptions and Limitations
  17. 1.7 Study Goals and Objectives
  18. 1.8 Years Considered
2 Global Meningococcal Disease Treatment Market Dynamics
  1. 2.1 Meningococcal Disease Treatment Industry Trends
  2. 2.2 Meningococcal Disease Treatment Industry Drivers
  3. 2.3 Meningococcal Disease Treatment Industry Opportunities and Challenges
  4. 2.4 Meningococcal Disease Treatment Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Meningococcal Disease Treatment Revenue by Company (2021-2026)
  2. 3.2 Global Meningococcal Disease Treatment Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Meningococcal Disease Treatment Key Company Head office and Area Served
  4. 3.4 Global Meningococcal Disease Treatment Company, Product Type & Application
  5. 3.5 Global Meningococcal Disease Treatment Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Meningococcal Disease Treatment Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Meningococcal Disease Treatment Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Meningococcal Disease Treatment Tier 1, Tier 2, and Tier 3
4 Meningococcal Disease Treatment Market by Type
  1. 4.1 Global Meningococcal Disease Treatment Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Meningococcal Disease Treatment Market Size by Type (2021-2032)
  3. 4.3 Global Meningococcal Disease Treatment Market Size Share by Type (2021-2032)
5 Meningococcal Disease Treatment Market by Application
  1. 5.1 Global Meningococcal Disease Treatment Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Meningococcal Disease Treatment Market Size by Application (2021-2032)
  3. 5.3 Global Meningococcal Disease Treatment Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Walvax Biotechnology Co.,Ltd.
  2. 6.1.1 Walvax Biotechnology Co.,Ltd. Company Information
  3. 6.1.2 Walvax Biotechnology Co.,Ltd. Business Overview
  4. 6.1.3 Walvax Biotechnology Co.,Ltd. Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Walvax Biotechnology Co.,Ltd. Meningococcal Disease Treatment Product Portfolio
  6. 6.1.5 Walvax Biotechnology Co.,Ltd. Recent Developments
  7. 6.2 Apeloa Pharmaceutical Co.,Ltd.
  8. 6.2.1 Apeloa Pharmaceutical Co.,Ltd. Company Information
  9. 6.2.2 Apeloa Pharmaceutical Co.,Ltd. Business Overview
  10. 6.2.3 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Treatment Product Portfolio
  12. 6.2.5 Apeloa Pharmaceutical Co.,Ltd. Recent Developments
  13. 6.3 Novartis
  14. 6.3.1 Novartis Company Information
  15. 6.3.2 Novartis Business Overview
  16. 6.3.3 Novartis Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Novartis Meningococcal Disease Treatment Product Portfolio
  18. 6.3.5 Novartis Recent Developments
  19. 6.4 Merck Sharp & Dohme
  20. 6.4.1 Merck Sharp & Dohme Company Information
  21. 6.4.2 Merck Sharp & Dohme Business Overview
  22. 6.4.3 Merck Sharp & Dohme Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Merck Sharp & Dohme Meningococcal Disease Treatment Product Portfolio
  24. 6.4.5 Merck Sharp & Dohme Recent Developments
  25. 6.5 Beijing Minhai Biological Technology Co.,Ltd.
  26. 6.5.1 Beijing Minhai Biological Technology Co.,Ltd. Company Information
  27. 6.5.2 Beijing Minhai Biological Technology Co.,Ltd. Business Overview
  28. 6.5.3 Beijing Minhai Biological Technology Co.,Ltd. Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Beijing Minhai Biological Technology Co.,Ltd. Meningococcal Disease Treatment Product Portfolio
  30. 6.5.5 Beijing Minhai Biological Technology Co.,Ltd. Recent Developments
  31. 6.6 CanSino Biologics Inc.
  32. 6.6.1 CanSino Biologics Inc. Company Information
  33. 6.6.2 CanSino Biologics Inc. Business Overview
  34. 6.6.3 CanSino Biologics Inc. Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 CanSino Biologics Inc. Meningococcal Disease Treatment Product Portfolio
  36. 6.6.5 CanSino Biologics Inc. Recent Developments
  37. 6.7 Shandong Jincheng Pharmaceutical Group Co.,ltd.
  38. 6.7.1 Shandong Jincheng Pharmaceutical Group Co.,ltd. Company Information
  39. 6.7.2 Shandong Jincheng Pharmaceutical Group Co.,ltd. Business Overview
  40. 6.7.3 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Treatment Product Portfolio
  42. 6.7.5 Shandong Jincheng Pharmaceutical Group Co.,ltd. Recent Developments
  43. 6.8 Pfizer
  44. 6.8.1 Pfizer Company Information
  45. 6.8.2 Pfizer Business Overview
  46. 6.8.3 Pfizer Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Pfizer Meningococcal Disease Treatment Product Portfolio
  48. 6.8.5 Pfizer Recent Developments
  49. 6.9 Hebei Hejia Pharmaceutical Technology Group Co., Ltd
  50. 6.9.1 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Company Information
  51. 6.9.2 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Business Overview
  52. 6.9.3 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Treatment Product Portfolio
  54. 6.9.5 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Recent Developments
  55. 6.10 GlaxoSmithKline
  56. 6.10.1 GlaxoSmithKline Company Information
  57. 6.10.2 GlaxoSmithKline Business Overview
  58. 6.10.3 GlaxoSmithKline Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 GlaxoSmithKline Meningococcal Disease Treatment Product Portfolio
  60. 6.10.5 GlaxoSmithKline Recent Developments
  61. 6.11 Chengdu Institute of Biology
  62. 6.11.1 Chengdu Institute of Biology Company Information
  63. 6.11.2 Chengdu Institute of Biology Business Overview
  64. 6.11.3 Chengdu Institute of Biology Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Chengdu Institute of Biology Meningococcal Disease Treatment Product Portfolio
  66. 6.11.5 Chengdu Institute of Biology Recent Developments
  67. 6.12 Sanofi Pasteur
  68. 6.12.1 Sanofi Pasteur Company Information
  69. 6.12.2 Sanofi Pasteur Business Overview
  70. 6.12.3 Sanofi Pasteur Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Sanofi Pasteur Meningococcal Disease Treatment Product Portfolio
  72. 6.12.5 Sanofi Pasteur Recent Developments
7 North America
  1. 7.1 North America Meningococcal Disease Treatment Market Size (2021-2032)
  2. 7.2 North America Meningococcal Disease Treatment Market Size by Type
  3. 7.2.1 North America Meningococcal Disease Treatment Market Size by Type (2021-2026)
  4. 7.2.2 North America Meningococcal Disease Treatment Market Size by Type (2027-2032)
  5. 7.2.3 North America Meningococcal Disease Treatment Market Share by Type (2021-2032)
  6. 7.3 North America Meningococcal Disease Treatment Market Size by Application
  7. 7.3.1 North America Meningococcal Disease Treatment Market Size by Application (2021-2026)
  8. 7.3.2 North America Meningococcal Disease Treatment Market Size by Application (2027-2032)
  9. 7.3.3 North America Meningococcal Disease Treatment Market Share by Application (2021-2032)
  10. 7.4 North America Meningococcal Disease Treatment Market Size by Country
  11. 7.4.1 North America Meningococcal Disease Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Meningococcal Disease Treatment Market Size by Country (2021-2026)
  13. 7.4.3 North America Meningococcal Disease Treatment Market Size by Country (2027-2032)
  14. 7.4.4 North America Meningococcal Disease Treatment Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Meningococcal Disease Treatment Market Size (2021-2032)
  2. 8.2 Europe Meningococcal Disease Treatment Market Size by Type
  3. 8.2.1 Europe Meningococcal Disease Treatment Market Size by Type (2021-2026)
  4. 8.2.2 Europe Meningococcal Disease Treatment Market Size by Type (2027-2032)
  5. 8.2.3 Europe Meningococcal Disease Treatment Market Share by Type (2021-2032)
  6. 8.3 Europe Meningococcal Disease Treatment Market Size by Application
  7. 8.3.1 Europe Meningococcal Disease Treatment Market Size by Application (2021-2026)
  8. 8.3.2 Europe Meningococcal Disease Treatment Market Size by Application (2027-2032)
  9. 8.3.3 Europe Meningococcal Disease Treatment Market Share by Application (2021-2032)
  10. 8.4 Europe Meningococcal Disease Treatment Market Size by Country
  11. 8.4.1 Europe Meningococcal Disease Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Meningococcal Disease Treatment Market Size by Country (2021-2026)
  13. 8.4.3 Europe Meningococcal Disease Treatment Market Size by Country (2027-2032)
  14. 8.4.4 Europe Meningococcal Disease Treatment Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Meningococcal Disease Treatment Market Size (2021-2032)
  2. 9.2 China Meningococcal Disease Treatment Market Size by Type
  3. 9.2.1 China Meningococcal Disease Treatment Market Size by Type (2021-2026)
  4. 9.2.2 China Meningococcal Disease Treatment Market Size by Type (2027-2032)
  5. 9.2.3 China Meningococcal Disease Treatment Market Share by Type (2021-2032)
  6. 9.3 China Meningococcal Disease Treatment Market Size by Application
  7. 9.3.1 China Meningococcal Disease Treatment Market Size by Application (2021-2026)
  8. 9.3.2 China Meningococcal Disease Treatment Market Size by Application (2027-2032)
  9. 9.3.3 China Meningococcal Disease Treatment Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Meningococcal Disease Treatment Market Size (2021-2032)
  2. 10.2 Asia Meningococcal Disease Treatment Market Size by Type
  3. 10.2.1 Asia Meningococcal Disease Treatment Market Size by Type (2021-2026)
  4. 10.2.2 Asia Meningococcal Disease Treatment Market Size by Type (2027-2032)
  5. 10.2.3 Asia Meningococcal Disease Treatment Market Share by Type (2021-2032)
  6. 10.3 Asia Meningococcal Disease Treatment Market Size by Application
  7. 10.3.1 Asia Meningococcal Disease Treatment Market Size by Application (2021-2026)
  8. 10.3.2 Asia Meningococcal Disease Treatment Market Size by Application (2027-2032)
  9. 10.3.3 Asia Meningococcal Disease Treatment Market Share by Application (2021-2032)
  10. 10.4 Asia Meningococcal Disease Treatment Market Size by Country
  11. 10.4.1 Asia Meningococcal Disease Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Meningococcal Disease Treatment Market Size by Country (2021-2026)
  13. 10.4.3 Asia Meningococcal Disease Treatment Market Size by Country (2027-2032)
  14. 10.4.4 Asia Meningococcal Disease Treatment Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Meningococcal Disease Treatment Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Meningococcal Disease Treatment Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Meningococcal Disease Treatment Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Meningococcal Disease Treatment Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Meningococcal Disease Treatment Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Meningococcal Disease Treatment Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Meningococcal Disease Treatment Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Meningococcal Disease Treatment Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Meningococcal Disease Treatment Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Meningococcal Disease Treatment Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Meningococcal Disease Treatment Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Meningococcal Disease Treatment Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Meningococcal Disease Treatment Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Meningococcal Disease Treatment Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst